NEWARK, California–(BUSINESS WIRE)–Oraya Therapeutics ha anunciado que la Sociedad alemana de oftalmología, la Sociedad de la Retina y la Asociación profesional de oftalmólogos alemanes, han emitido una opinión conjunta sobre el uso de la radioterapia junto con el sistema IRay® de radioterapia estereotáctica para la degeneración macular relacionada con la edad neovascular. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de
NEWARK, Calif.–(BUSINESS WIRE)–Oraya Therapeutics heeft vandaag bekendgemaakt dat de Duitse Oogheelkundige Vereniging, de Retina Society en de Vereniging voor Duitse Oogheelkundigen een gezamenlijk oordeel over het gebruik van radiotherapie in combinatie met IRay® Stereotactic Radiotherapy System voor neovasculaire, leeftijdsgerelateerde maculadegeneratie. Dit oordeel geeft een richtlijn voor de selectie en behandeling van patiënten met bijkomende radiotherapie die ondergeschikt is aan therap
HOUSTON–(BUSINESS WIRE)–Eye Elegance recently opened the doors to their new second location at 1703 Post Oak Blvd. in the Galleria/Uptown Park area. On Wednesday, October 14th, VIP guests were invited to the new store.
LARGO, Fla.–(BUSINESS WIRE)–Ken Beckman, MD, President of CEDARS/ASPENS has stated, “We would like to extend our sincere thanks to Allergan, Bausch + Lomb, Shire, and Omeros for their annual support of CEDARS/ASPENS and for their enthusiasm and foresight in supporting the Society. These Annual Sponsorships as well as our Conference Sponsorships allow us to continue our work in shaping the future of anterior segment care through Innovation, Collaboration, and Education (I·C·E.) We look forward
NEEDHAM, Mass. & PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Tyrogenex, a privately held biopharmaceutical company, today announced plans to present at the 14th Annual BIO Investor Forum in San Francisco on Wednesday, Oct. 21, 2015, at 9:30 a.m. PDT.
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Eleven Biotherapeutics completed patient enrollment in its first pivotal, Phase 3 clinical study of isunakinra (EBI-005) in patients with moderate to severe allergic conjunctivitis.
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the development and commercialization of innovative therapies for diseases and conditions of the eye, today announced the enrollment of the first patients in a third Phase 3 clinical trial for DEXTENZATM (sustained release dexamethasone) 0.4mg Intracanalicular Depot, for the treatment of post-surgical ocular inflammation and pain. Based on the results of the Company’s two previously c
ARLINGTON, Va.–(BUSINESS WIRE)–The CEA Foundation is pleased to announce the winners of its first “technology that improves lives” video contest. Aipoly, HelpAround, Los Angeles Low Vision, Perceptive Devices and WHILL were selected from more than 20…
STOCKHOLM–(BUSINESS WIRE)–Regulatory News: Tobii AB (STO:TOBII) plans to publish the interim report for the period January 1—September 30 on November 3 at 08.00 CET. Following this report Tobii will arrange a conference call with web cast presentation for investors, analysts and media. Tobii’s President and CEO Henrik Eskilsson and CFO Esben Olesen will present and comment on the report. After the presentation there will be time for questions. The presentation will be held in English. Time Tu
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, which develops drug therapies for eye diseases, announces completion of Phase 2 clinical trial enrollment for treatment of macular edema associated with non-infectious uveitis.
CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that data from the TIME-2 Phase 2a Study of AKB-9778 in the treatment of patients with diabetic macular edema (DME) will be presented at the upcoming American Academy of Ophthalmology (AAO) Annual Meeting’s Retina Subspecialty Day. In July, the company announced data showing that a combination of AKB-9778 and Lucentis® provided significa
TUCSON, Ariz.–(BUSINESS WIRE)–Photometrics, a manufacturer of high performance scientific cameras for life science applications, today announces the release of its new sCMOS camera, the Photometrics Prime. Prime is the first 4.2 Megapixel scientific CMOS camera available for life science research that actively defeats the negative impact of Poisson noise in low light images. The camera packs a formidable FPGA-based Embedded Signal Processing engine, ESP™, that enables powerful signal restorat
BOULOGNE-BILLANCOURT, France–(BUSINESS WIRE)–Regulatory News: Cegedim, an innovative technology and services company, today announced the signature of an agreement for the acquisition of the US based Practice Management business of Nightingale Informatix Corporation by its US subsidiary Pulse System, Inc. The acquisition includes the assets of Nightingale’s Medrium, Ridgemark, Secure Connect and Northern Health Products. Jeff Burton, the Pulse Systems President and CEO stated that “We are exc
DUBLIN–(BUSINESS WIRE)–Presbia PLC (NASDAQ: LENS), an ophthalmic device company introduced its new, innovative disposable inserter for the Presbia Flexivue Microlens™ at the Australasian Society of Cataract and Refractive Surgeons (AUSCRS) conference held from October 7th through the 10th in Noosa, Queensland, Australia. The Presbia Flexivue Microlens is a proprietary optical lens implant for treating presbyopia, the age-related loss of near-vision. With its simplified action, the new inserte
MIAMI–(BUSINESS WIRE)–Cirle, Inc., a Miami-based medical technology incubator, has won the prestigious “Red Dot Award-Best of the Best” for its 3-D Surgical Navigation System prototype in international design competition.
SAARBRÜCKEN y HEIDELBERG–(BUSINESS WIRE)–URSAPHARM, una de las empresas líderes en el campo de la oftalmología en Europa, y Novaliq, empresa farmacéutica especializada en estudios clínicos con una plataforma tecnológica para la distribución de fármacos centrada en la oftalmología, han anunciado hoy un acuerdo de colaboración así como el lanzamiento europeo de EvoTears™. El comunicado en el idioma original, es la versión oficial y autorizada del mismo. La traducción es solamente un medio de ay
MINNEAPOLIS–(BUSINESS WIRE)–Today’s kids use digital devices for hours daily, which may have long term consequences for their eyes and vision. An annual comprehensive eye exam is essential for all children as they enter school.
OULU, Finland–(BUSINESS WIRE)–Optomed Oy, Finland based and the world’s fastest growing retinal company received significant investment from Robert Bosch Venture Capital GmbH (RBVC), Germany. “This investment will be used to accelerate growth across the business, to advance our product development and help us to successfully execute our strategy. It is a big recognition towards both our technology and our team in Finland. We are proud to welcome RBVC as one of our investors. With their suppor
NEWARK, Kalifornien (USA) und NIZZA (Frankreich)–(BUSINESS WIRE)–Oraya Therapeutics Inc. gab heute bekannt, dass führende Ophthalmologen aus drei europäischen Ländern auf einem Symposium im Rahmen des 15. Kongresses der europäischen Gesellschaft der Netzhautspezialisten in Nizza an der französischen Riviera die Ergebnisse für die Patienten ein Jahr nach einer einmaligen Behandlung mit der Oraya Therapy für feuchte altersbedingte Makuladegeneration (Age-related Macular Degeneration, AMD) präse
NEWARK, Californie et NICE, France–(BUSINESS WIRE)–Oraya Therapeutics Inc. a annoncé aujourd’hui que d’éminents ophtalmologues de trois pays européens ont présenté les résultats du suivi de patients un an après un traitement unique par la thérapie Oraya contre la dégénérescence maculaire liée à l’âge (DLMP) exsudative, au cours d’un symposium lors du 15e congrès de la Société européenne des spécialistes de la rétine à Nice, France. Les résultats montrent que la thérapie Oraya est efficace dan